ASCL4 (achaete-scute family bHLH transcription factor 4) is a transcriptional regulator with emerging roles in ferroptosis and metabolic homeostasis. While the gene was previously annotated as potentially involved in skin development based on sequence homology, recent evidence reveals that ASCL4 functions primarily as a key mediator of ferroptosis—an iron-dependent form of programmed cell death triggered by lipid peroxidation. ASCL4 catalyzes the synthesis of arachidonoyl-CoA from arachidonic acid, promoting ferroptosis execution, and remodels phospholipid composition in cell membranes and mitochondria 1. In cancer contexts, ASCL4 upregulation by acetylated STAT3 increases phospholipid synthesis and mitochondrial integrity, enabling chemoresistance in triple-negative breast cancer 2; conversely, in KRAS-mutant pancreatic cancer, suppression of ASCL4 via autophagy-dependent degradation enhances ferroptosis sensitivity and synergizes with anti-PD-1 immunotherapy 3. ASCL4 is also dysregulated in acute kidney injury 4, Alzheimer's disease 5, ulcerative colitis 6, and preeclampsia 7, where inhibiting its expression or activity reduces ferroptosis-driven pathology. In gastric cancer, tumor-associated neutrophil-derived exosomes suppress ASCL4 to promote chemoresistance 8. These findings position ASCL4 as a therapeutic target in ferroptosis-related diseases, with potential clinical applications in overcoming cancer chemoresistance and limiting pathogenic ferroptosis in neurodegeneration and organ injury.